ArticleNeurology and therapy2025
Efficacy and Safety of Tenecteplase in the Treatment of Acute Branch Atheromatous Disease: A Retrospective Multicenter Case-Control Study.
Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Preemptive vs. Conventional Tirofiban Administration on the Outcomes in Acute Branch Atheromatous Disease: A Propensity Score-Weighted Cohort Study.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionBranch atheromatous disease (BAD) is a common subtype of acute ischemic stroke characterized by atherosclerosis. Patients with BAD are highly prone to early neurological deterioration. Intravenous thrombolysis can restore blood flow. We investigated the efficacy of tenecteplase (TNK) intravenous thrombolysis in BAD treatment.
methodsWe retrospectively examined data from patients with BAD admitted to 13 hospitals in Zhengzhou between January 2020 and December 2024. Participants were categorized into TNK and dual antiplatelet therapy (DAPT) groups. Propensity score matching was performed to reduce subgroup heterogeneity.
resultsWe included 1980 patients (TNK: 621, DAPT: 1359) matched in 522 pairs of participants. After propensity score matching, intravenous TNK administration within 4.5 h of stroke onset was associated with reduced early neurological deterioration (unadjusted odds ratio [OR] = 1.796, 95% confidence interval [CI]: 1.303-2.477, P < 0.001) and improved clinical outcomes 90 days post-stroke. In the TNK group, more patients achieved good functional prognosis (modified Rankin scale [mRS] 0-1; unadjusted OR = 0.648, 95% CI 0.506-0.830, P < 0.001) and were functionally independent (mRS 0-2) at 90 days post-stroke (unadjusted OR = 0.725, 95% CI 0.546-0.963, P = 0.026). The dependence rate (mRS ≥ 4) in the TNK group was significantly lower than that in the DAPT group (unadjusted OR = 1.576, 95% CI 1.062-2.339, P = 0.024). Mortality (unadjusted OR = 2.351, 95% CI 0.605-9.143; P = 0.217), symptomatic intracranial hemorrhage (unadjusted OR = 0.595, 95% CI 0.215-1.650; P = 0.319), and other bleeding events (unadjusted OR = 1.371, 95% CI 0.680-2.764; P = 0.378) did not differ significantly.
conclusionTNK intravenous thrombolysis may be a safe and effective treatment for patients with BAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.